Trial · NCT07906561
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Serum GDF-15 Concentration | Within 24 hours of ICU admission and at 72 hours | Serum growth differentiation factor-15 (GDF-15) concentration measured by enzyme-linked immunosorbent assay (ELISA), in pg/mL. |
| Primary | Serum LGALS3BP Concentration | Within 24 hours of ICU admission and at 72 hours | Serum galectin-3-binding protein (LGALS3BP) concentration measured by enzyme-linked immunosorbent assay (ELISA), in µg/mL. |
| Primary | 28-Day All-Cause Mortality | 28 days after ICU admission | Number of participants who died from any cause within 28 days of ICU admission. |
| Primary | Change in SOFA Score | From ICU admission to 72 hours | Change in Sequential Organ Failure Assessment (SOFA) score from ICU admission to 72 hours. The SOFA score ranges from 0 to 24, with higher scores indicating more severe organ dysfunction. |
| Secondary | Change in Serum GDF-15 Concentration | From ICU admission to 72 hours | Change in serum GDF-15 concentration measured by ELISA between ICU admission and 72 hours, in pg/mL. |
| Secondary | Change in Serum LGALS3BP Concentration | From ICU admission to 72 hours | Change in serum LGALS3BP concentration measured by ELISA between ICU admission and 72 hours, in µg/mL. |
| Secondary | Area Under the ROC Curve of the Combined GDF-15 and LGALS3BP Panel for 28-Day Mortality | 28 days after ICU admission | Area under the receiver operating characteristic curve (range 0 to 1) of the combined serum GDF-15 and LGALS3BP panel for predicting 28-day all-cause mortality. |
| Secondary | APACHE II Score | Within 24 hours of ICU admission | Acute Physiology and Chronic Health Evaluation II score at ICU admission. Scores range from 0 to 71, with higher scores indicating greater disease severity. |
| Secondary | Number of Participants Requiring Vasopressor Therapy | From ICU admission to 72 hours | Number of participants requiring vasopressor therapy to maintain mean arterial pressure. |
| Secondary | Duration of Invasive Mechanical Ventilation | From ICU admission to extubation or death, assessed up to 28 days | Duration of invasive mechanical ventilation, in days. |
| Secondary | ICU Length of Stay | From ICU admission to ICU discharge, assessed up to 28 days | Length of intensive care unit stay, in days. |
| Secondary | In-Hospital All-Cause Mortality | From ICU admission to hospital discharge, assessed up to 28 days | Number of participants who died from any cause during the hospital stay. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07906561/registered